Evidence map›Paper›PMID 31895446›Full record

ArticleJAMA ophthalmology2020

Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival.

Manuel Rodrigues, Khadija Ait Rais, Flore Salviat, Nathalie Algret, Fatoumata Simaga, Raymond Barnhill, Sophie Gardrat, Vincent Servois, Pascale Mariani, Sophie Piperno-Neumann and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Ocular Melanoma: A Comprehensive Review with a Focus on Molecular Biology.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Uveal Melanoma and Kidney Cancer: More Similar than Meets the Eye.Kidney cancer journal : official journal of the Kidney Cancer Association · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Manuel RodriguesUnit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Khadija Ait RaisDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Flore SalviatDepartment of Biometry, Institut Curie, PSL Research University, Paris, France.
Nathalie AlgretDepartment of Biometry, Institut Curie, PSL Research University, Paris, France.
Fatoumata SimagaDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Raymond BarnhillDepartment of Biopathology, Institut Curie, PSL Research University, Paris, France.
Sophie GardratUnit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Vincent ServoisDepartment of Medical Imaging, Institut Curie, PSL Research University, Paris, France.
Pascale MarianiDepartment of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.
Sophie Piperno-NeumannDepartment of Medical Oncology, Institut Curie, PSL Research University, Paris, France.
Sergio Roman-RomanDepartment of Translational Research, Institut Curie, PSL Research University, Paris, France.
Olivier DelattreUnit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Nathalie CassouxFaculty of Medicine, University of Paris Descartes, Paris, France.
Alexia SavignoniDepartment of Biometry, Institut Curie, PSL Research University, Paris, France.
Marc-Henri SternUnit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France.
Gaëlle PierronDepartment of Genetics, Institut Curie, PSL Research University, Paris, France.
Institut Curie · FRUniversité Paris Sciences et Lettres · FRZimmer Biomet (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Studies on uveal melanomas (UMs) have demonstrated the prognostic value of 8q gain and monosomy 3, but the prognosis of UMs with partial deletion of chromosome 3 remains to be defined. Objective: To examine the association of partial chromosome 3 deletion in UMs with metastasis-free survival. Design, Setting, and Participants: This retrospective cohort study of 1088 consecutive comparative genomic hybridization arrays performed from May 1, 2006, to July 31, 2015, assessed patients presenting with UMs with and without partial loss of chromosome 3 at a referral center. Data analysis was performed from September 1, 2017, to November 30, 2017. Exposure: Uveal melanoma with or without partial loss of chromosome 3. Main Outcomes and Measures: Metastasis-free survival and overall survival at 60 months. Results: Of the 1088 consecutive comparative genomic hybridization arrays that were performed, 43 UMs (4.0%) in 43 patients (median age, 58 years [range, 12-79 years]; 22 [51%] female) carried partial deletions of chromosome 3. Median follow-up was 66 months (range, 1.2-126.2 months). Metastasis-free survival at 60 months was 33.6% (95% CI, 15.8%-71.4%) for UMs that carried a deletion of the BAP1 (BRCA1 associated protein 1) locus (BAP1del; 24 tumors) and 80.5% (95% CI, 64.8%-100%) for UMs without the loss of the BAP1 locus (BAP1 normal [BAP1nl]; 19 tumors) (log-rank P = .001). Overall survival at 60 months was 64.5% (95% CI, 43.5%-95.8%) in the BAP1del group vs 84.1% (95% CI, 69.0%-100%) in the BAP1nl group (log-rank P < .001). In these 43 cases, metastasis-free survival at 60 months was 100% for UMs without loss of the BAP1 locus or 8q gain, 70.0% (95% CI, 50.5%-96.9%) for UMs that carried 1 of these alterations, and 12.5% (95% CI, 2.1%-73.7%) for those that carried both (log-rank P < .001). Similarly, overall survival at 60 months was 100% for UMs without loss of the BAP1 locus or 8q gain, 80.8% (95% CI, 63.3%-100%) for UMs that carried 1 of these alterations, and 46.7% (95% CI, 23.3%-93.6%) for those that carried both (log-rank P < .001). Conclusions and Relevance: These findings suggest that partial deletion of chromosome 3 encompassing the BAP1 locus is associated with poor prognosis. A cytogenetic classification of UMs could be proposed based on the status of the BAP1 locus instead of the chromosome 3 locus, while also taking chromosome 8q into account.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 3AdolescentAdultAgedChildFemaleGenetic LociHumansMaleMelanomaMiddle AgedNeoplasm MetastasisRetrospective StudiesTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID31895446
PMCPMC6990836
OpenAlexW2998306588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.